Megaprosthesis use in Paprosky III/IV femoral defects in non-oncological patients: analysis of survival, clinical, and functional outcomes after an average follow-up of five years

被引:2
|
作者
Ribera, Juan [1 ,2 ]
Payo-Ollero, Jesus [1 ,2 ]
Serrano-Toledano, David [1 ,2 ]
del Rio-Arteaga, Marta [1 ,2 ]
Montilla, Francisco Javier [1 ,2 ]
Muela, Rafael [1 ,2 ]
机构
[1] Clin COT, C Juan Ramon Jimenez 29, Seville 41011, Spain
[2] Hosp Viamed Santa Angela Cruz, Orthoped Surg & Traumatol Dept, Ave Jerez 59, Seville 41014, Spain
关键词
Proximal femoral replacement; Megaprosthesis; Bone loss; Femur; Arthroplasty; TOTAL HIP-ARTHROPLASTY; REVISION HIP; BONE LOSS; REPLACEMENT; SYSTEM; RECONSTRUCTION; CLASSIFICATION; TUMORS;
D O I
10.1007/s00590-023-03783-9
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Purpose To determine the survival and patient-reported outcomes in non-oncological patients treated with proximal femoral resection (PFR) using MEG for femoral reconstruction.Materials and methods This retrospective study included 16 patients. Demographic variables and complications developed were analyzed. Clinical-functional outcomes were measured using the modified Harris score (mHSS), numeric Pain Rating Scale (NPRS) and Musculoskeletal Tumor Society (MSTS) score. MEG survival was estimated using a Kaplan-Meier survival analysis.Results Average follow-up was 5 years (range, 1-9). The 75% of patients were overweight and women with an average age of 74.2 +/- 5.9-years (BMI of 28.5 +/- 4.2 kg/m2). The main cause of MEG was periprosthetic infection (43.7%). The 50% of patients had post-surgical complications regarding with MEG, being the most frequent seromas and MEG dislocation. Implant survival was 93.4% and 80.9% at 3 and 7 years of follow-up, respectively. The functional results at the end of the follow-up with respect to the pre-surgical state improved from 9.5 +/- 2.6 to 3 +/- 0.9 mean NPRS and 26.5 +/- 6.8 to 69.5 +/- 13.5 mean mHHS, p < 0.001, respectively. The mean MSTS score was 68.1% that these results were considered excellent.Conclusions The MEG for reconstruct III-IV femoral defects is a good therapeutic option that offers an acceptable clinical functional result. Short-term and medium-term survival was greater than 80%. The most frequent complications are seromas and MEG dislocation. The use of constrained liner and abductor system reconstruction is essential to prevent the dislocation.
引用
收藏
页码:1183 / 1192
页数:10
相关论文
共 23 条
  • [21] Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP versus primary retroperitoneal lymph node dissection: A 13-years follow-up analysis of a phase III trial cohort.
    Hiester, Andreas
    Fingerhut, Anna
    Niegisch, Guenter
    Siener, Roswitha
    Krege, Susanne
    Schmelz, Hans U.
    Dieckmann, Klaus-Peter
    Heidenreich, Axel
    Kwasny, Peter
    Pechoel, Maik
    Lehmann, Jan
    Kliesch, Sabine
    Koehrmann, Kai Uwe
    Fimmers, Rolf
    Loy, Volker Volker
    Wittekind, Christian
    Hartmann, Michael
    Albers, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection- A 13-year follow-up analysis of a phase III trial cohort
    Hiester, Andreas
    Fingerhut, Anna
    Niegisch, Gunter
    Siener, Roswitha
    Krege, Susanne
    Schmelz, Hans-Ulrich
    Dieckmann, Klaus-Peter
    Heidenreich, Axel
    Kwasny, Peter
    Pechoel, Maik
    Lehmann, Jan
    Kliesch, Sabine
    Koehrmann, Kai-Uwe
    Fimmers, Rolf
    Loy, Volker
    Wittekind, Christian
    Hartmann, Michael
    Albers, Peter
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 64 - 72
  • [23] Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
    Caixeta, Adriano
    Lansky, Alexandra J.
    Serruys, Patrick W.
    Hermiller, James B.
    Ruygrok, Peter
    Onuma, Yoshinobu
    Gordon, Paul
    Yaqub, Manejeh
    Miquel-Hebert, Karine
    Veldhof, Susan
    Sood, Poornima
    Su, Xiaolu
    Jonnavithula, Lalitha
    Sudhir, Krishnankutty
    Stone, Gregg W.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (12) : 1220 - 1228